Histological architectural classification determines recurrence pattern and prognosis after curative hepatectomy in patients with hepatocellular carcinoma

Aim The clinical impact of pathological classification based on architectural pattern in hepatocellular carcinoma (HCC) remains elusive in spite of its well-known and common feature. Methods The prognostic impact of pathological classification was examined with prospective database. Three hundred and eighty HCC patients who underwent curative hepatectomy as an initial treatment in Kumamoto University were enrolled as a test cohort. The outcome was confirmed with a validation cohort in Kyushu University. Results Macrotrabecular (macro-T) subtype (n = 38) and compact subtype (n = 43) showed similar biological and prognostic features. Both showed higher AFP level and worse overall survival than microrabecular (micro-T) subtype (n = 266). Multivariate analysis for overall survival revealed that DCP ≥ 40, multiple tumor and macro-T/compact subtype were associated with poor overall survival (risk ratio = 2.2, 1.6 and 1.6; p = 0.002, 0.020, and 0.047, respectively). Of note, 32% of macro-T/compact subtype showed early recurrence within 1 year, which showed substantially low (5%) 5 year overall survival, whereas 16% of micro-T/PG subtype did. Twenty-one percent of macro-T/compact subtype showed multiple intrahepatic metastases (≥ 4) or distant metastases, which resulted in non-curative treatment, whereas 5% of micro-T/PG subtype did. In validation cohort, macro-T/compact subtype was an independent predictor of worse overall survival. Conclusion Macro-T/compact subtype is biologically discriminated from micro-T and PG subtypes due to its aggressive features and poor prognosis after curative treatment. Additional treatment with curative hepatectomy on Macro-T/compact subtype should be discussed because of high possibility of systemic residual cancer cell.

[1]  T. Han,et al.  Shp2 promotes liver cancer stem cell expansion by augmenting β‐catenin signaling and predicts chemotherapeutic response of patients , 2017, Hepatology.

[2]  J. Zucman‐Rossi,et al.  Genetic Landscape and Biomarkers of Hepatocellular Carcinoma. , 2015, Gastroenterology.

[3]  M. Roncalli,et al.  YAP activation is an early event and a potential therapeutic target in liver cancer development. , 2014, Journal of hepatology.

[4]  X. Wang,et al.  EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features. , 2009, Gastroenterology.

[5]  C. Mathers,et al.  Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 , 2010, International journal of cancer.

[6]  M. Makuuchi,et al.  Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial. , 2015, The Lancet. Oncology.

[7]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[8]  A. Villanueva,et al.  Genetic profiling of hepatocellular carcinoma using next-generation sequencing. , 2016, Journal of hepatology.

[9]  H. Honda,et al.  Clinical usefulness of 18F‐fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma , 2013, Hepatology research : the official journal of the Japan Society of Hepatology.

[10]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[11]  A. Belldegrun,et al.  Adjuvant Weekly Girentuximab Following Nephrectomy for High-Risk Renal Cell Carcinoma: The ARISER Randomized Clinical Trial , 2017, JAMA oncology.

[12]  Yan Lu,et al.  Alpha fetoprotein plays a critical role in promoting metastasis of hepatocellular carcinoma cells , 2016, Journal of cellular and molecular medicine.

[13]  Masatoshi Kudo,et al.  Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial , 2017, The Lancet.

[14]  J. Pastorek,et al.  Hypoxia-induced carbonic anhydrase IX as a target for cancer therapy: from biology to clinical use. , 2015, Seminars in cancer biology.

[15]  Claudiu T. Supuran,et al.  Recent Developments in Targeting Carbonic Anhydrase IX for Cancer Therapeutics , 2012, Oncotarget.

[16]  K. Batts,et al.  Prognostic Histologic Indicators of Curatively Resected Hepatocellular Carcinomas: A Multi-institutional Analysis of 425 Patients With Definition of a Histologic Prognostic Index , 2002, The American journal of surgical pathology.

[17]  J. Habbema,et al.  Prognostic Modeling with Logistic Regression Analysis , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[18]  Bin Zhang,et al.  Clinicopathological indices to predict hepatocellular carcinoma molecular classification , 2016, Liver international : official journal of the International Association for the Study of the Liver.

[19]  S. Hayami,et al.  Triple Positive Tumor Markers for Hepatocellular Carcinoma Are Useful Predictors of Poor Survival , 2011, Annals of surgery.

[20]  D. Zopf,et al.  Regorafenib (BAY 73‐4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity , 2011, International journal of cancer.

[21]  A. Belldegrun,et al.  ARISER: A randomized double blind phase III study to evaluate adjuvant cG250 treatment versus placebo in patients with high-risk ccRCC—Results and implications for adjuvant clinical trials. , 2013 .

[22]  K. Jang,et al.  Immunohistochemical Expression and Clinical Significance of Suggested Stem Cell Markers in Hepatocellular Carcinoma , 2015, Journal of pathology and translational medicine.

[23]  G. Tiberio,et al.  Early and Late Recurrence After Liver Resection for Hepatocellular Carcinoma: Prognostic and Therapeutic Implications , 2006, Annals of surgery.